A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma
NCT01881529 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 29
Last updated 2014-04-17
Summary
To treat patients with scleroderma by blocking the expression of LOXL2. The investigators first need to confirm (through observation) that LOXL2 is overexpressed in disease.
Conditions
- Limited Scleroderma
- Diffuse Scleroderma
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bittoo Kanwar, MD · Gilead Sciences
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-04-30
- Primary Completion
- 2014-03-31
- Completion
- 2014-03-31
Countries
- Australia
Study Locations
More Related Trials
-
A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
NCT00442611 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Lysyl Oxidase, Semaphorin 7a and Semaphorin 3a in Patients With Systemic Sclerosis
NCT01943968 ·Status: UNKNOWN ·Phase: NA
-
Studies of Dermatologic Diseases Biospecimen Acquisition Protocol
NCT02471352 ·Status: RECRUITING
-
Evaluation of SclerFIX Graft in Scleral Thinning After Exeresis of Tumors of the Ocular Surface
NCT05302609 ·Status: TERMINATED ·Phase: PHASE2
-
The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)
NCT02887495 ·Status: COMPLETED
-
IL1-TRAP, Rilonacept, in Systemic Sclerosis
NCT01538719 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
NCT00377949 ·Status: COMPLETED
-
A Study of the Safety and Tolerability of MEDI-551 in Scleroderma
NCT00946699 ·Status: COMPLETED ·Phase: PHASE1
-
Analysis of Cytokine Expression Pattern in Systemic Sclerosis
NCT03537105 ·Status: COMPLETED ·Phase: NA
-
Skin Biopsy Specimens as Biomarkers of Systemic Sclerosis and Response to Mycophenolate Mofetil
NCT00853788 ·Status: COMPLETED
-
A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
NCT04837131 ·Status: TERMINATED ·Phase: PHASE2
-
Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis
NCT03041025 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis
NCT03508375 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
NCT02283762 ·Status: COMPLETED ·Phase: PHASE2
-
A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy
NCT00936546 ·Status: COMPLETED ·Phase: PHASE2
-
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
NCT06599411 ·Status: NOT_YET_RECRUITING
-
Longitudinal Spatial Frequency Domain Imaging Study
NCT05672992 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Empirical Comparative Study of Variation Blood Level Antibody Vitamin D at Scleroderma (SSc) Patients Compared Healthy Peoples
NCT01553890 ·Status: UNKNOWN ·Phase: NA
-
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
NCT02370693 ·Status: COMPLETED ·Phase: PHASE2
-
Imatinib in Systemic Sclerosis
NCT00506831 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma
NCT01553981 ·Status: COMPLETED ·Phase: PHASE3
-
The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis
NCT06546540 ·Status: RECRUITING ·Phase: PHASE4
-
Treatment of Early Systemic Sclerosis by Bosentan
NCT00226889 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of Scaling Disorders and Other Inherited Skin Diseases
NCT00001292 ·Status: COMPLETED
-
Platform Clinical Study for Conquering Scleroderma
NCT06195072 ·Status: RECRUITING ·Phase: PHASE2